Birkenstock Q3 FY26 revenue beat but EPS miss: growth solid, margin pressure evident

What happened

Birkenstock reported Q3 FY26 revenue of €719.53 million, slightly ahead of expectations of €713.54 million, but failed to beat on EPS, signaling cost or margin headwinds. The top-line beat confirms ongoing consumer willingness to pay for the brand, consistent with the master report's view of a high-quality franchise with mid-teens growth. However, the EPS miss likely reflects tariff impacts, FX translation, or expense inflation, areas already flagged as risks. The stock continues to trade at a rich valuation (~24x TTM EPS, ~17x EV/EBITDA) despite a ~16% 12-month price decline, leaving little room for execution stumbles. Overall, the quarter reinforces the WAIT stance from the master report: brand strength is intact, but the price still embeds aggressive assumptions.

Implication

The revenue beat supports the demand thesis, but the EPS miss suggests the margin compression risks flagged in the master report are materializing, likely from U.S. tariffs on EU-made goods and FX headwinds. At current multiples, the market is still pricing in sustained double-digit growth and margin stability, which now appears less certain given this quarter's bottom-line shortfall. Investors should closely monitor the next few quarters for confirmation of tariff pass-through, cost controls, and any changes to guidance, especially the FY26 adjusted EPS range of €1.90–2.05. Until governance issues (material weaknesses in internal controls) and leverage/TRA obligations are fully resolved, the risk-reward remains unattractive for new long positions. A better entry would be either a significant price pullback toward conservative DCF levels or clear evidence that margin pressures are temporary and reversible.

Thesis delta

The thesis remains unchanged: Birkenstock is a high-quality brand with durable growth, but current valuation offers insufficient margin of safety. The Q3 revenue beat confirms top-line resilience, while the EPS miss adds near-term evidence to existing tariff/FX margin risks. No shift from WAIT is warranted; the stock only becomes attractive on a valuation reset or confirmed margin stabilization.